{Reference Type}: Journal Article
{Title}: Axillary Management Following Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer.
{Author}: Mitri S;Roldan-Vasquez E;Flores R;Pardo J;Borgonovo G;ScD RBD;James TA;
{Journal}: Clin Breast Cancer
{Volume}: 0
{Issue}: 0
{Year}: 2024 May 21
{Factor}: 3.078
{DOI}: 10.1016/j.clbc.2024.05.008
{Abstract}: <B>BACKGROUND: </B>Clinical trial data indicate that omitting axillary lymph node dissection (ALND) is feasible and may reduce morbidity for carefully selected patients with clinically node-positive breast cancer who achieve a pathological complete response (pCR) after neoadjuvant chemotherapy (NCT). However, there remains a need to understand how these findings translate to broader clinical practice and to identify which patients benefit most. This study utilizes a national dataset to assess outcomes in axillary management, aiming to inform best practice in axillary de-escalation.<BR><B>METHODS: </B>The National Cancer Data Base was used to identify women diagnosed with clinically node-positive invasive breast cancer between 2012 to 2020 who received NCT and subsequent ALND. Associations between clinicopathologic factors and axillary pCR were analyzed statistically.<BR><B>RESULTS: </B>Of the 59,791 patients included, 8,827 (14.76%) achieved nodal pCR. Patients with HR-negative and HER2-positive receptor status more frequently underwent ALND instead of sentinel lymph node biopsy. Conversely, patients over the age of 70, those with private or public insurance, and cases classified as ypT1 or ypT2 were less likely to undergo ALND.<BR><B>CONCLUSIONS: </B>A subset of patients with clinically node-positive breast cancer received ALND despite achieving axillary pCR following NCT. This highlights an opportunity to enhance precision in identifying candidates for axillary de-escalation, potentially reducing morbidity and tailoring treatment more closely to individual patient needs.